FANCA and prostate adenocarcinoma: To explore the potential role of FA pathway gene expression in prostate cancer patient outcome, we analyzed the overall and progression-free survival rates of patients with high and low expression of FA pathway genes using The Cancer Genome Atlas (TCGA) prostate adenocarcinoma (TCGA-PRAD; N = 498; (48)) and Stand Up to Cancer (SU2C; N = 444; (49)) metastatic castration-resistant prostate cancer cohorts.